2012 Current Cancer Dedicated to bringing the latest news and information on cancer diagnosis, treatment and prevention.


Clinical Trials for Oncology

Advertiment

Innovative approaches to optimise the time and cost of getting your cancer drugs through the clinic

26 – 28 September 2011 Massachusetts

How innovative approaches in trial design and execution can drive your development of next-generation cancer therapies…
Clinical trials are the most expensive part of the drug development process, and the design and execution of oncology trials in particular is becoming more complex than ever before.
But there is a growing field of knowledge and expertise, enabling the industry’s leading players to maximise the chances of their cancer drugs succeeding in the clinic and beyond.
This year’s Clinical Trials for Oncology conference will focus on how you can bring your clinical trials in line with important developments in personalized medicine, targeted therapeutics and adaptive trial design.
Inspired and designed by the world’s leading drug developers, the meeting will bring you 14 industry case studies to show how your peers are actively putting innovative scientific concepts into practice:
Kelly White, Manager, Global Trial Optimization TA Lead: Oncology, Merck will show how you can model and simulate biomarker defined populations to accurately identify the biologically targeted sub-populations that will benefit from your treatment and inform your operational planning.
Lilli Petruzzelli, Translational Medicine Group, Novartis Institutes for BioMedical Research will discuss proof of concept and how you can make your early phase trials better indicators of later success.
Debasis Chakrabarti, Therapy Area Head, Oncology Global Medical and Clinical Affairs, Baxter Healthcare will reveal the latest innovations in targeted therapies for cancers.
Jean-Pierre Bizzari, Senior Vice President, Clinical Oncology/Hematology, Celgene Corporation will investigate the importance of adaptive clinical trial design and surrogate endpoints as potential solutions to the emerging challenges in oncology trials.
Marie Anne Stager, Director, Clinical Operations, Seattle Genetics will explain how she has increased the efficiency of initial and registration studies for a cancer drug by partnering with a variety of clinical research organizations.
Peter Langmuir, Executive Director, Medical Science, AstraZeneca will take you through the recent development and approval of vandetanib, a targeted therapy for medullary thyroid carcinoma.
Julie Lisano, Director, Clinical Science – Oncology, Regeneron Pharmaceuticals will draw from her current experience of evaluating the role of biomarkers in a phase III oncology trial to show how you can use biomarkers to assess drug effectiveness.
Susan Thurston, Director, Clinical Protocol Manager – Oncology, Pfizer will reveal how you can ensure excellent communication between different sites to successfully manage large-scale, international trials.
Gang Chen, Director, Biostatistics, Johnson & Johnson will give expert insights enabling you to take full advantage of the opportunities to run trials in emerging regions.
To find out what other key topics will be addressed at the event, click here for the full agenda.
Clinical Trials for Oncology brings together medical and clinical professionals working in oncology trials from the world’s leading pharmaceutical and biotechnology companies. Click here to see the full list of speakers who will be sharing their expertise and experience at the event.
You will leave Clinical Trials for Oncology knowing how to fully exploit new opportunities in emerging regions, adaptive trial design, biomarker integration and end-point determination. Most importantly, you will be able to optimise the time and cost of getting your cancer drugs through the clinic and into the market.

Venue & Accommodation

Radisson Hotel Boston
200 Stuart Street
Boston, Massachusett
02116, USA

Reservations: 1-800-395-7046 US/Canada
Toll-free. Telephone: (617) 482-1800

http://www.radisson.com/boston-hotel-ma-02116/maboston

Contact
Speak with a member of the team: +44 (0) 203 141 8700
Write to us:

Hanson Wade
Charter House
13-15 Carteret Street
London
SW1H 9DJ
Email: info@hansonwade.com

Related Search

debasis chakrabarti 2012,
Clinical Trials for Oncology: 07.01.2011 · Posted in Cancer Conferences, Publications Tags: ,

Leave a Reply

Suggested Posts

3rd World Circulating Tumor Cells Summit I ovative approaches to optimise the time a d cost of getti g your ca cer drugs through the cli ic 26 – 28 September 2011 Massachusetts How i ovative approaches i trial desig a d executio ca drive your developme t of ext-ge eratio ca cer therapies… Cli ical trials are the most expe sive part of the drug developme t process, a d the desig a d executio [...]. Posted July 1st, 2011 | 4:59 am
Lilly’s Global Sourcing Strategy Model for Oncology Optimization I ovative approaches to optimise the time a d cost of getti g your ca cer drugs through the cli ic 26 – 28 September 2011 Massachusetts How i ovative approaches i trial desig a d executio ca drive your developme t of ext-ge eratio ca cer therapies… Cli ical trials are the most expe sive part of the drug developme t process, a d the desig a d executio [...]. Posted July 1st, 2011 | 4:59 am
Chicago Live 2011: Endoscopic Advances in Gastrointestinal Malignancies I ovative approaches to optimise the time a d cost of getti g your ca cer drugs through the cli ic 26 – 28 September 2011 Massachusetts How i ovative approaches i trial desig a d executio ca drive your developme t of ext-ge eratio ca cer therapies… Cli ical trials are the most expe sive part of the drug developme t process, a d the desig a d executio [...]. Posted July 1st, 2011 | 4:59 am
Spa Oncology Training Summit I ovative approaches to optimise the time a d cost of getti g your ca cer drugs through the cli ic 26 – 28 September 2011 Massachusetts How i ovative approaches i trial desig a d executio ca drive your developme t of ext-ge eratio ca cer therapies… Cli ical trials are the most expe sive part of the drug developme t process, a d the desig a d executio [...]. Posted July 1st, 2011 | 4:59 am
Mouse Models of Cancer I ovative approaches to optimise the time a d cost of getti g your ca cer drugs through the cli ic 26 – 28 September 2011 Massachusetts How i ovative approaches i trial desig a d executio ca drive your developme t of ext-ge eratio ca cer therapies… Cli ical trials are the most expe sive part of the drug developme t process, a d the desig a d executio [...]. Posted July 1st, 2011 | 4:59 am